My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
Allocation Agreement with exhibits - final
>
Meetings
>
2022
>
09. September
>
2022-09-06 10:00 AM - Commissioners' Agenda
>
Allocation Agreement with exhibits - final
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
9/1/2022 1:11:41 PM
Creation date
9/1/2022 1:10:08 PM
Metadata
Fields
Template:
Meeting
Date
9/6/2022
Meeting title
Commissioners' Agenda
Location
Commissioners' Auditorium
Address
205 West 5th Room 109 - Ellensburg
Meeting type
Regular
Meeting document type
Supporting documentation
Supplemental fields
Item
Request to Approve a Resolution Authorizing the Chair's Signature on a Opioid Litigation Allocation Agreement
Order
3
Placement
Consent Agenda
Row ID
93293
Type
Agreement
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
106
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
FINAL AGREEMENT 3.25.22 <br />Schedule B <br />Approved Uses <br />Support treatment of Opioid Use Disorder (OUD) and any co-occurring Substance Use Disorder <br />or Mental Health (SUD/MH) conditions through evidence -based or evidence -informed programs <br />or strategies that may include, but are not limited to, the following: <br />PART ONE: TREATMENT <br />A. TREAT OPIOID USE DISORDER (OUD) <br />Support treatment of Opioid Use Disorder ("OUD") and any co-occurring Substance Use <br />Disorder or Mental Health ("SUD/MH") conditions through evidence -based or evidence - <br />informed programs or strategies that may include, but are not limited to, those that: 15 <br />1. Expand availability of treatment for OUD and any co-occurring SUD/MH <br />conditions, including all forms of Medication -Assisted Treatment ("MAT") <br />approved by the U.S. Food and Drug Administration. <br />2. Support and reimburse evidence -based services that adhere to the American <br />Society of Addiction Medicine ("ASAM") continuum of care for OUD and any co- <br />occurring SUD/MH conditions. <br />3. Expand telehealth to increase access to treatment for OUD and any co-occurring <br />SUD/MH conditions, including MAT, as well as counseling, psychiatric support, <br />and other treatment and recovery support services. <br />4. Improve oversight of Opioid Treatment Programs ("OTPs") to assure evidence - <br />based or evidence -informed practices such as adequate methadone dosing and low <br />threshold approaches to treatment. <br />5. Support mobile intervention, treatment, and recovery services, offered by <br />qualified professionals and service providers, such as peer recovery coaches, for <br />persons with OUD and any co-occurring SUD/MH conditions and for persons <br />who have experienced an opioid overdose. <br />6. Provide treatment of trauma for individuals with OUD (e.g., violence, sexual <br />assault, human trafficking, or adverse childhood experiences) and family <br />members (e.g., surviving family members after an overdose or overdose fatality), <br />and training of health care personnel to identify and address such trauma. <br />7. Support evidence -based withdrawal management services for people with OUD <br />and any co-occurring mental health conditions. <br />15 As used in this Schedule B, words like "expand," "fund," "provide" or the like shall not indicate a preference for <br />new or existing programs. <br />E-4 <br />
The URL can be used to link to this page
Your browser does not support the video tag.